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Objectives: Enterotoxigenic Escherichia coli (ETEC), a major cause of diarrhea in children under
5,  is an important agent for traveler’s diarrhea. Heat-labile enterotoxin (LT) and colonization
factors  (CFs) are two main virulence mechanisms in ETEC. CS6 is one of the most prevalent
CFs  consisting of two structural subunits viz., CssA, CssB, necessary for attachment to the
intestinal  cells.
Methods:  In the present research, a chimeric trivalent protein composed of CssB, CssA and
LTB  was constructed. The chimeric gene was synthesized with codon bias of E. coli for
enhanced  expression of the protein. Recombinant proteins were expressed and puriﬁed.
Mice  were immunized with the recombinant protein. The antibody titer and speciﬁcity of
the immune sera were analyzed by ELISA and Western blotting. Efﬁciency of the immune
sera  against ETEC was evaluated.
Results: Antibody induction was followed by immunization of mice with the chimeric pro-
tein.  Pretreatment of the ETEC cells with immunized animal antisera remarkably decreased
their  adhesion to Caco-2 cells.Discussion:  The results indicate efﬁcacy of the recombinant chimeric protein as an effective
immunogen,  which induces strong humoral response as well as protection against ETEC
adherence  and toxicity.
or  both LT or ST are expressed, resulting in diarrheal disease.
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroduction
Enterotoxigenic Escherichia coli (ETEC) is one of the important
agents  causing diarrhea in children under ﬁve years old in
developing  countries and is a major cause of diarrhea in trav-
elers  to those regions.1,2 This microorganism is responsible for
400,000 to 800,000 deaths per year.3 ETEC strains have several
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Este é um artigo Open Access sob a licençavirulence factors like heat-labile enterotoxin (LT), heat-stable
enterotoxin (ST) and colonization factors (CFs).1 CFs are sur-
face  proteins that mediate adherence to intestinal mucosa, the
ﬁrst  step to begin pathogenesis.4 Following adherence, either
5Of more  than 25 identiﬁed CFs,6 CS6 is one of the most
epidemiologically prevalent CF in many  countries, often
accounting for up to 20–30% of all clinical isolates.1,4 This has
 de CC BY-NC-ND
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ed to interest to try to use CS6 alone or in combination with
ther  antigens in an ETEC vaccine.1,7 The morphology of CS6
s  non-ﬁmbrial and is expressed either alone or with CS5 or
ess  commonly with CS4 on ETEC strains.7,8
The genes associated with CS6 are expressed as a typical
acterial operon, consisting of four genes viz., cssA, cssB, cssC,
nd  cssD.7 CssA and CssB are structural subunits, whereas
ssC  and CssD are recognized to be chaperone and usher
espectively.9 CssC protein assists in the folding of the CssA
nd  CssB structural subunits, and CssD has been ascribed
n  usher function responsible for transport of CssA and
ssB  to the cell surface.7 40 kDa CssA and 15.5 kDa CssB are
ecessary  for attachment to intestinal cells.4,7 The CssA inter-
cted  with the host cell ﬁbronectin while CssB binds to cell
urface  sulfatide.4,10 Studies have indicated that antibodies
gainst both structural subunits are essential to inhibit the
dhesion.1,4
LT toxin consists of a pentameric ring of ﬁve identical
inding (LTB) subunits of 11.5 kDa surrounding an active sub-
nit  (LTA) and bind strongly to the intestinal receptor GM1
n  the surface of eukaryotic cells.11,12 The B subunit mostly
ssociates with immunity against LT and induces both sys-
emic  and mucosal antibody responses.13 Since most clinical
TEC  isolates can produce LT and has adjuvant properties,
herefore it is a suitable candidate antigen to provide anti-LT
mmunity.14,15
In order to provide protection, an ETEC vaccine should
nclose the most prevalent CF and a LT toxoid or B subunit
f  LT toxin until it blocks adherence and toxin activity.5,16
Because live attenuated or killed bacterial cell vaccines are
otentially  associated with transient side effects, use of sub-
nit  vaccines has been preferred. The subunit vaccines are
onsiderably safe immune system stimulators with the ability
o  target the site where immunity is required.17
In this study a trivalent recombinant protein was  designed
gainst  ETEC CS6 strains. A construction containing struc-
ural  subunits of CS6 (CssB, and 100 amino acids from the
-terminal of the protein CssA) and B subunit of LT toxin
as  designed. The immunogenicity of a trivalent recombinant
rotein  coded by a synthetic gene is reported.
aterials  and  methods
acterial  strains,  plasmids  and  media
TEC strains were  isolated from children with diarrhea. The
trains  were  previously characterized for the presence of CFs
nd enteroxins and used for challenge purpose. Plasmids pET-
8a  and pET-32a were from Novagen (USA). E. coli BL21 (DE3),
H5  and Top10 were  procured from Pasteur Institute of Iran.
he  E. coli strains were grown in Luria–Bertani (LB) broth at
7 ◦C.
n  silico  predictions  and  construction  of  chimeric  genehimeric gene was  designed based on the nucleotide
equence of ltb, cssA and cssB genes (Gen Bank accession
umbers; M17874.1, GQ241328.1, UO4844.1, respectively). The
equences  were  used to generate a chimeric trivalent protein4;1 8(3):308–314  309
fused  together by (EAAAK)4 hydrophobic linkers in order to
ﬁnd  the best epitope exposing chimeric antigen. The in silico
gene  analysis and multi parameter gene optimization of the
synthetic  chimeric gene was  performed using OPTIMIZER
server. Itasser and phyre software were used in order to esti-
mate  tertiary structure prediction. The chimeric proteins were
analyzed  for B-cell epitopes using Bcepred server. The gene
encoding  protein was  synthesized by Shine Gene Molecular
Biotech, Inc. (Shanghai, China).
Expression  and  puriﬁcation  of  chimeric  protein
The synthetic gene (cssA- cssB -ltB) subcloned into pET28a was
transformed  to E. coli BL21 (DE3) (Novagen). The transformants
were grown in Luria Bertani (LB) broth supplemented with
30  g of kanamycin/ml. Expression of the chimeric protein
was  induced at OD600 of 0.5 by addition of 1 mM isopropyl--
d-galactopyranoside (IPTG) and analyzed by sodium dodecyl
sulfate  polyacrylamide gel electrophoresis (SDS-PAGE). Batch
puriﬁcation  of His-tagged proteins from E. coli under dena-
turing  conditions (Qiagen) was  carried out and validated by
SDS-PAGE.  The denaturant (8 M urea) was removed by stepwise
dialysis.
Western  blot  analysis
The proteins separated by SDS-PAGE were blotted onto nitro-
cellulose  membrane using transfer buffer (39 mM glycine,
48  mM Tris–base, 0.037% SDS, and 20% methanol). The mem-
brane  was  incubated in 10 ml  blocking buffer (5% skim milk
in  PBST [137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4 and
0.05%  (v/v) Tween-20]) at 4 ◦ C overnight. The membrane was
then  incubated in a 1:10,000 dilution of mice anti-His-tag -
conjugated  HRP and anti-CTX (Sigma) in the PBST, with mild
shaking  for 1 h at 37 ◦C. Detection was  carried out using
HRP  staining solution containing 3,3′-diaminobenzidine (DAB)
(Sigma)  and H2O2.
Animal  immunization
Five-week old female BALB/C mice and New Zealand White
female  rabbits procured from Pasteur Institute of Iran were
randomly  divided into test and control groups. Animals were
immunized  four times. Each mouse received 20 g recom-
binant CS6 protein along with complete Freund’s adjuvant
(SIGMA) subcutaneously. Booster doses of 15 and 10 g recom-
binant  proteins with incomplete Freund’s adjuvant were
injected  after 20 and 35 days, respectively. PBS served as con-
trol  in parallel to the aforementioned procedure. The sera
taken  from animal blood after the second and third injections
were  stored at −70 ◦C for further analyses.
Determination  of  serum  IgG  responses  to  recombinant
proteins
Indirect ELISA was used for antibody titration. A 96-well ELISA
plates  (Nunc) were coated with 5 g of CssA, CssB and LTB
proteins  in coating buffer (64 mM Na2CO3, 136 mM NaHCO3,
pH  9.8) at 4 ◦C overnight. The plates were washed three times
with  PBST and the non-speciﬁc sites were blocked with skim
i s . 2 0 1 4;1  8(3):308–314
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Fig. 1 – Design and modeled tertiary structure of chimeric
protein: (A) schematic construction of recombinant chimeric
protein  containing CssB, CssA and LTB bound together by
appropriate  linkers, (B) amino acid sequences of chimeric
protein  and (C) modeled tertiary structure of chimeric
protein by I-TASSER software. This model showed a protein
with  three main domains linked together with linkers.310  b r a z j i n f e c t d 
milk solution 5% (w/v) in PBST. The serum samples serving as
primary antibodies were serially diluted to 1:500 in PBST and
added  to the ELISA plates with incubation at 37 ◦C for 45 min.
The  plates were  washed thrice in PBST and Goat Anti-Mouse
IgG  Antibody (12,000 in PBST) was  added to the ELISA plates as
the secondary antibody. The plates were  incubated for 30 min
at 37 ◦C and were  then washed. The wells added with 100 l of
citrate  buffer containing 0.06% (W/V) of O-phenylene diamine
dihydrochloride (OPD) (SIGMA) and 0.06% (V/V) hydrogen per-
oxide  were  incubated at room temperature for 15 min. The
reaction  was  stopped with 100 l of 2 M H2SO4 and the OD492
was  read on a microplate reader (Bio-Rad).
ETEC  binding  inhibition  assay
Caco-2 cells (104/well) were  added and grown to conﬂuence in
96-well plates with DMEM supplemented with 10% (v/v) FBS
at  37 ◦C in a culture ﬂask. ETEC strain was  grown in LB broth.
The  bacterial suspension (105/well) was  pretreated with 40 l
of immunized mice antisera for 15 min  at room temperature.
The  bacterial mixture was  added to Caco-2 cells and incubated
for  2 h at room temperature. The supernatant was decanted,
and  the cells were  washed with PBS. After digestion, the sus-
pended  bacteria were  serially diluted and incubated in LB agar
at  37 ◦C for 16 h. Subsequently, the number of bacteria adhered
to  the Caco-2 cells was  counted. The sera of non-immunized
mice were  used as control.
Anti-LT  antibody  neutralization
The production of LT toxin neutralizing antibodies was  per-
formed  with rabbit ileal loop, cAMP immunoassay and Y-1
cell  rounding assay. The rabbit ileal loop test was  carried out
according  to the methods described by De and Chatterjee.18
New Zealand White rabbits (1.5 kg) were  fasted for 24 h before
surgery.  The rabbits were anesthetized by the intramuscu-
lar  injection of fentanyl (SIGMA) (0.3 ml/kg of body weight)
and  zolazepam chloridrate (0.4 ml/kg of body weight). 10-cm
ligated  ileal loops were  constructed. ETEC at 1 × 108 con-
centration were  incubated with mouse serum raised against
the  chimeric protein, for 30 min. ETEC bacteria incubated
with  non-immune mouse serum served as negative control.
The  above bacterial mixture and PBS were inoculated into
each  ligated loop using a 25-gauge needle. After 18 h, the
Table 1 – The predicted B-cell epitopes from full-length
chimeric protein.
Epitopes Amino acid positions Scores
IVPENVSQVTVYPVYDEDYG 11 1
NYTSGDKEIPPGIYNDQVMV 76 0.992
LVNVNNPDQNMNYYIRKDSG 195 0.98
FYSNEAAAKEAAAKEAAAKE 263 0.975
DDSQSIIYQIVDDKGKKMLK 39 0.956
TFKSGATFQVEVPGSQHIDS 327 0.94
SVKENTSYTFSAIYTGGEYP 227 0.921
KSLDVNVNIEQNFIPDIDSA 126 0.894
RIIPVNYDSDPKLNSQLYTV 147 0.845
TELCSEYRNTQIYTINDKIL 292 0.825
ERMKDTLRITYLTETKIDKL 352 0.802animals were sacriﬁced with intravenous 3% pentobarbital,
and zolazepam chloridrate (0.4 ml/kg). For each ileal loop,
the  volume of secretion was  measured after excision. Experi-
mental  infection of the rabbits was performed at the Faculty
of  Veterinary Medicine, University of Tehran. Research was
conducted  in compliance with the Animal Welfare Act and
regulations related to experiments involving animals. The
production  of antibodies that neutralized LT toxin was also
performed  with a cAMP immunoassay kit (Abnova) and CHO
cells.  CHO cells were seeded in 24-well sterile culture plates
at  a density of 5 × 104 cells per well and were grown overnight
to  approximately 80% conﬂuence. 0.1 g of LT was  incubated
with  50 l mice serum at room temperature for 1 h, and the
mixture  was  added to each well for incubation at 37 ◦C in 5%
CO2 for 2 h After washes, the cells were lysed with 0.1 M HCl
and  the supernatant was  used in cAMP assay following the
manufacturer’s protocol.
For  cell rounding assay, Y-1 mouse adrenal cells (Pasteur
Institute of Iran) were seeded in cell culture plates at a con-
centration of 5 × 104 cells per well and grown to conﬂuence
at  37 ◦C/5% CO2 atmosphere. Y-1 cells were  mixed with LT
pretreated  with serum samples and incubated under 5% CO2
b r a z j i n f e c t d i s . 2 0 1 4;1 8(3):308–314  311
Fig. 2 – Expression and puriﬁcation of recombinant chimeric protein: (A) SDS-PAGE analysis of the rCS6 expression after
IPTG induction. Lane 1: protein weight marker. Lanes 2, 4: non induced cells. Lane 3: the induced bacteria. (B) Puriﬁcation of
rCS6 protein by Ni-NTA column. Lane 1: protein weight marker. Lane 2: expression of chimeric protein. Lane 3:
ﬂow-through. Lane 4: column washed with buffer D (pH = 5.9). Lane 5: column washed with elution buffer (pH = 4.5). Lane 6:
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ncubator at 37 ◦C for 10 h. The morphological changes were
bserved  under the compound microscope.
tatistical  analysis
ll statistical analyses were conducted using a SPSS 12.0 sta-
istical  program.  Student’s t-test was  used to analyze the
ata  for antibody responses between immunized and non-
mmunized  groups; t-test was  also used to evaluate the
igniﬁcance of differences in inhibition of ETEC binding to
aco-2  cells generated by test sera. A value of p < 0.05 was
onsidered statistically signiﬁcant.
esults
odon  optimization  and  tertiary  structure  prediction
 chimeric trivalent protein fused together by (EAAAK)4
ydrophobic linkers in order to ﬁnd the best epitope expos-
ng  chimeric antigen (Fig. 1A and B). Codon optimization
as  performed to improve the transcription efﬁciency and
ranscript  stability. Percentage of codon having a frequency
istribution of 91–100 in the native chimeric CS6 gene was
6%,  which was  signiﬁcantly improved to 91% in the opti-
ized  gene sequence. The overall GC content, which is
 measure of transcriptional and translational efﬁciency,
as  improved from 38.96% to 48.75% upon codon optimiza-
ion.  There were ﬁve negative cis elements in the native
S6  gene sequence, which were  removed after optimiza-
ion.Ab  initio modeling of the synthetic sequence was  exploited
o  produce 3D models of the chimeric protein. The result of
ertiary  structure of the chimeric protein construction using
-TASSER  showed a protein with three main domains linkedtogether  with linker (Fig. 1C). B-cell epitope was predicted
and  the epitopes having cutoff values >0.8 were  selected
(Table 1).
Expression  and  puriﬁcation  of  recombinant  protein
The genes were  subcloned into pET28a and pET32a vectors
respectively and over expressed in E. coli (BL21DE3) (Fig. 2A).
The  SDS-PAGE analysis showed the presence of a 47 KD
recombinant chimeric protein. The puriﬁcation of recombi-
nant  proteins was carried out under denaturation condition
by  Ni-NTA afﬁnity (Fig. 2B). The expression of the recombi-
nant  protein was  conﬁrmed by the detection of the protein
by  Western blot using anti-His-tag and anti CTX antibodies
(Fig.  3).
Response  to  immunization  with  recombinant  protein
Animals were immunized with the recombinant chimeric pro-
tein. All immunized animals had anti-CssA, anti-CssB, and
anti-LT  IgG antibodies detected in serum (Fig. 4).
Inhibition  of  ETEC  binding  to  Caco-2  cells
Assessment of Caco-2 cell monolayers revealed that ETEC
cells  pretreated with serum from non-immunized mice were
distributed  on the Caco-2 cells. However, pretreatment of
the  ETEC cells with immunized mice antisera considerably
blocked their binding to Caco-2 cells. The immune sera could
inhibit  68 ± 3.5% bacterial adhesion onto the target cells. Com-
parison  of pretreatment of the bacteria with non-immune
antisera with that of immunized mice serum, showed a con-
siderable  reduction in their adhesion to Caco-2cells followed
by  pretreatment of the ETEC cells with immunized mice anti-
sera.
312  b r a z j i n f e c t d i s . 2 0 1 4;1  8(3):308–314
Fig. 3 – Western blot analysis rCS6: (A) using anti
6X-His-tag antibodies. Lane 1: protein weight marker. Lane
2:  rCS6 and (B) using anti-CTXB. Lane 1: protein weight
marker, Lane 2: rCS6, Lane 3: antibody. Negative control
(bacterial lysate without IPTG induction).
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Fig. 4 – Serum anti-LTB, -CssB, and -CssA antibody titers of
mice immunized with chimeric protein. Titers calculated as
log 10 of last reciprocal dilution above cut-off. Error bars
represent  mean ± SEM (n = 3).
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Fig. 5 – Anti-LT antibodies neutralization assay with cAMP
immunoassay. Serum samples from immunized or from
the  control mice were tested to neutralize LT toxin. Cyclic
AMP  concentrations of treated CHO cells were measured
using  a cAMP kit. Mean values are shown, and error bars
represent  standard deviations.
Anti-LT  toxin  antibody  neutralization  assay
For each ileal loop, the volume of secretion measured
after excision was  as follows: ETEC as a positive con-
trol:  2.59 ± 0.3 g/cm, ETEC+ antisera: 0.51 ± 0.01 g/cm, PBS:
0.31  ± 0.12 g/cm. The ﬂuid accumulation was not observed
in  rabbit ileal loops 18 h post-infection with ETEC treated
with  the immunized mice serum. In contrast, infection with
standard  ETEC was  accompanied by an increase of ﬂuid secre-
tion.  Data from the cAMP immunoassay kit showed that
antibodies in serum and fecal samples of the immunized
mice neutralized LT and prevented the toxin from stimulating
intracellular cyclic AMP levels in CHO cells (Fig. 5). No mor-
phological changes were observed in Y1 cells incubated with
LT  pretreated with anti-chimeric antibody, whereas normal
serum  had no inhibitory effects on rounding (Fig. 6).
Discussion
A vaccine against ETEC could have a signiﬁcant impact on mor-
bidity  and mortality caused by diarrheal diseases in children
living  in developing countries.19 ETEC vaccine development
has been based on two strategies of blocking adherence and/or
toxin  activity.5 A trivalent recombinant protein was  designed
consisting of CssB, CssA, LTB subunits.
The production of chimeras consisting of ETEC adhesion
and  enterotoxin B subunit may  be capable of eliciting both
antitoxin  and anti-adhesion immune responses.16 Chimeric
method reduces the need for producing three separate anti-
gens,  which would make it more  cost-effective and would ease
the  manufacturing process.
In  the present study LTB reported to be expressed by over
half  of LT expressing ETEC isolates was  used, the presence
b r a z j i n f e c t d i s . 2 0 1 4;1 8(3):308–314  313
Fig. 6 – Inhibitory effect of anti-L2C3 antibody on the rounding of Y-1 cells. Y-1 cells were  co-cultured with LT pretreated
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f antibody against LTB can block the binding of the toxin
o  epithelial cells.14,20 LTB shows adjuvant effect that elicited
trong  humoral and cellular immune response against the
accine  components.15,21 On the other hand, although ST
ntigens are prevalent in ETEC isolates, they cannot be used
s  vaccine components for their poor immunogenicity.11
ssB have been reported as a key factor for binding to
ost  cells7 and a hundred amino acids from the C-terminal
egion of CssA have been reported to interact with the host
ell  ﬁbronectin.4 We combined three fragments with link-
rs  (EAAAK)4. Chimeric proteins with a helical linker are
hought  to have a more  elongated conformation compared
o  those with a ﬂexible linker. (EAAAK)4 sequences were
ntroduced between different domains for more  ﬂexibility
nd  efﬁcient separation. The successful experience of using
EAAAK)4  sequences in chimeric gene has paved the way for
t  to bring about rationally acceptable results.17 The recombi-
ant  protein was  conﬁrmed by western blot using anti-His-tag
conjugated HRP and anti-CTXB antiserum as LTB is struc-
urally  very similar to B subunit of cholera toxin (CTXB).
he  puriﬁed rCS6 was  used for immunization of mice and
abbit.  In order to achieve an optimal induction and power-
ul  response, we  applied booster doses at least three weeks
fter  the ﬁrst injection. The doses were gradually decreased
o  increase afﬁnity and to fully activate the B-cell immune
ascade. The ELISA test results indicated that the immu-
ized  animals produced higher titer of anti-chimer antibody
han  each individual gene (to each individual gene alone) and
mmunization  with chimeric rCs6 strongly protected animals
rom  ETEC challenges. Accordingly a signiﬁcant difference in
ntibody titer was  observed between sera of the immunize
nimals and control groups. The ﬁnding further indicates that
-cell  epitopes of this chimeric protein might be located in
hree  distinct parts, selected as the CssA, CssB, and LTB.
The  adhesion inhibition capacity of the antibodies raised
gainst  the recombinant chimer protein assayed with Caco-2
ells  revealed that pretreatment of ETEC with immunized mice
ntisera decreased their adhesion properties and blocked their
inding to Caco-2 cells. Attachment to epithelial cell culture
f  ETEC was  effectively reduced in immunized mice compared
o  the control. This is consistent with the reports indicatingthat CssA, CssB were  necessary for attachment to intestinal
cells.4,7
The ability of the antibodies against rCS6 to block ﬂuid
accumulation was  tested in rabbit intestinal loops. The results
indicate  that rCS6 antibody is capable of binding to the toxin
and  neutralizing its effect. Vaccination with a recombinant
chimeric trivalent immunogen could protect the host against
ETEC.  Pretreatment of the ETEC cells with immunized mice
antisera  remarkably decreased their adhesion properties and
blocked  their binding to Caco-2 cells.
Since mucosal immunity, especially the production of IgA
antibodies,  is thought to be important for blocking the attach-
ment  of E. coli to epithelial cells, the latter aspect, such as
the  application of the chimeric recombinant protein in oral
administration, should be considered in further immunization
studies. However, it has been demonstrated with Citrobacter
rodentium that secretory IgA is not necessary for preventing
bacterial colonization in mice using intimin as a vaccine
antigen.22
In conclusion, our chimeric protein not only induced anti-
toxins  neutralizing antibodies, but also induced anti-adhesion
antibodies for protecting against ETEC. The ﬁndings are in
support  of its use as an immunogen protein toward taking
advantage of its components in vaccine strategies against
ETEC.
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